Multiple myeloma, or plasma cell myeloma, is the second most common cancer of the blood. Multiple myeloma accounts for approx. 1% of all cancers and 2% of all deaths from cancer. Multiple myeloma is a disease in which malignant plasma cells spread through the bone marrow. These myeloma cells may form tumors called plasmacytomas. Eventually, multiple soft spots or holes, called osteolytic lesions, form in the bones.
Scientists develop vaccine that attacks breast cancer in mice — Implications for the treatment of ovarian, colorectal and pancreatic cancer, as well – Researchers have developed a vaccine that dramatically reduces tumors in a mouse model that mimics 90 percent of human breast and pancreatic cancer cases-including those that are resistant to common treatments.
Multiple myeloma patients experience high response rate with new 3-drug combination – A new three-drug combination has shown in a phase 1/2 clinical trial that it is a “highly effective regimen” in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.
JNCI news brief: Thalidomide does not improve survival in small cell lung cancer – Treating patients with thalidomide in combination with chemotherapy for small cell lung cancer (SCLC) did not improve their survival but did increase their risk of blood clots, revealed by researchers.
Getting down to cancer basics — Cancer mutations in the heart of gene regulation. – Researchers have identified a new cancer gene – one that is common to many cancers and affects the most basic regulation of our genes.
Stress may hasten the growth of melanoma tumors but common beta-blocker medications might slow that progress. – For patients with a particularly aggressive form of skin cancer malignant melanoma stress, including that which comes from simply hearing that diagnosis, might amplify the progression of their disease.
Cancer drug bortezomib ? used to treat multiple myeloma – effectively treats organ transplant rejections. – University of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection.
Emory University researchers have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important “intercept points” for cancer cells. – Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important “intercept points” for cancer cells.
